The medication stimulates brain receptors that reduce appetite, making users feel less hungry and crave less
While some studies suggest a possible correlation between GLP-1 RAs and intestinal obstruction, others report no significant association, with discrepancies likely due to variations in study demographics, methodologies, and GLP-1 RA formulations
Daily use friendly 25
the rationale is based on the fact that improved glycemia restores sensitivity to GIP [14, 16] and peptide engineering enables the design of hybrid ligands exhibiting dual agonism, as proved in experimental studies [19]
Subgroup analyses showed that compared to sitagliptin, the exenatide group had a significant reduction in total cholesterol (0.16 mmol/L, 0.29 to 0.03, I 2 = 0%, P = 0.34) and no significant increase in HDL cholesterol (0.02 mmol/L, 0.05 to 0.02, I 2 = 0%, P = 0.68)